Conjugates and Malignant Disease

Conjugates and Malignant Disease PDF

Author: Michael Magerstadt

Publisher: CRC Press

Published: 1991-01-03

Total Pages: 246

ISBN-13: 9780849360893

DOWNLOAD EBOOK →

This book provides a comprehensive overview of antibody conjugates for in vivo applications. It discusses each of the major classes of antibody conjugates used in cancer diagnosis and therapy, as well as the major chemical and biological aspects of antibody selection, conjugate preparation, characterization, and application. The book is designed to close the information gap that exists regarding these compounds between such diverse disciplines as radiochemists, immunochemists, oncologists, clinicians and immunologists. It also provides a thorough overview for newcomers to the field.

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer PDF

Author: Sara Hurvitz

Publisher: Elsevier Health Sciences

Published: 2018-07-26

Total Pages: 264

ISBN-13: 0323581234

DOWNLOAD EBOOK →

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Immunoconjugates

Immunoconjugates PDF

Author: Carl-Wilhelm Vogel

Publisher: Oxford University Press, USA

Published: 1987

Total Pages: 330

ISBN-13:

DOWNLOAD EBOOK →

Immunoconjugate research aims to develop improved methods of cancer detection and more effective, efficient drugs to combat cancer. This book contains contributions from virtually all established research groups in the immunotoxin field and offers a comprehensive discussion of current and potential applications of immunoconjugates, covering all pertinent topics from chemical synthesis to clinical trial.

Antibody-Drug Conjugates and Immunotoxins

Antibody-Drug Conjugates and Immunotoxins PDF

Author: Gail Lewis Phillips

Publisher: Springer Science & Business Media

Published: 2012-12-13

Total Pages: 370

ISBN-13: 1461454565

DOWNLOAD EBOOK →

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Antibody-Drug Conjugates

Antibody-Drug Conjugates PDF

Author: Kenneth J. Olivier, Jr.

Publisher: John Wiley & Sons

Published: 2016-11-14

Total Pages: 560

ISBN-13: 111906080X

DOWNLOAD EBOOK →

Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development

Innovations for Next-Generation Antibody-Drug Conjugates

Innovations for Next-Generation Antibody-Drug Conjugates PDF

Author: Marc Damelin

Publisher: Springer

Published: 2018-05-29

Total Pages: 357

ISBN-13: 3319781545

DOWNLOAD EBOOK →

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

Cytotoxic Payloads for AntibodyDrug Conjugates

Cytotoxic Payloads for AntibodyDrug Conjugates PDF

Author: David E Thurston

Publisher: Royal Society of Chemistry

Published: 2019-07-11

Total Pages: 502

ISBN-13: 1788018451

DOWNLOAD EBOOK →

Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.

Antibody-Drug Conjugates

Antibody-Drug Conjugates PDF

Author: Laurent Ducry

Publisher: Humana Press

Published: 2013-08-03

Total Pages: 317

ISBN-13: 9781627035422

DOWNLOAD EBOOK →

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular BiologyTM format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.

Antibody Fusion Proteins

Antibody Fusion Proteins PDF

Author: Steven M. Chamow

Publisher: Wiley-Liss

Published: 1999-04-13

Total Pages: 312

ISBN-13: 9780471183587

DOWNLOAD EBOOK →

Thoroughly detailed and illustrated, this book examines the construction, properties, applications, and problems associated with specific types of fusion molecules used in clinical and research medicine. The editors present an overview of the field, followed by nine chapters divided into two general sections based on the two primary parts of the antibody molecule: Fab fusion proteins and Fc fusion proteins. In addition, numerous renowned scientists in the field have contributed outlines demonstrating man-made molecules that will be required not only to overcome the limitations of monoclonal antibodies, but also to extend the principle of selective targeting. Divided into specific, accessible sections, Antibody Fusion Proteins includes: * Chapters describing Fc fusion proteins, as well as several classes of antigen-binding proteins * Complete details on the design and molecular construction of genetically engineered fusion molecules * Useful information on molecular purification, large-scale production, practical applications, and their therapeutic potential * The latest data on forming fusion proteins with toxins, cytokines, or enzymes that can activate a prodrug

How Tobacco Smoke Causes Disease

How Tobacco Smoke Causes Disease PDF

Author:

Publisher:

Published: 2010

Total Pages: 728

ISBN-13:

DOWNLOAD EBOOK →

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.